Ocular Therapeutix (NASDAQ:OCUL) Hits New 52-Week Low – Here’s What Happened

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) reached a new 52-week low during trading on Thursday. The company traded as low as $5.78 and last traded at $5.8340, with a volume of 614,997 shares trading hands. The stock had previously closed at $5.94.

Analyst Upgrades and Downgrades

OCUL has been the subject of several recent research reports. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Ocular Therapeutix in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a research note on Monday, October 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $23.00 price target on shares of Ocular Therapeutix in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.83.

Read Our Latest Stock Report on Ocular Therapeutix

Ocular Therapeutix Trading Down 1.6%

The company has a 50 day moving average of $7.68 and a 200 day moving average of $8.85. The company has a current ratio of 9.12, a quick ratio of 9.05 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -4.01 and a beta of 1.22.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The business had revenue of $12.87 million during the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The company’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.38) EPS. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -1.61 EPS for the current year.

Insider Transactions at Ocular Therapeutix

In other news, insider Namrata Saroj sold 35,370 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total value of $231,673.50. Following the transaction, the insider directly owned 220,522 shares in the company, valued at $1,444,419.10. This trade represents a 13.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $7.05, for a total transaction of $76,626.45. Following the completion of the sale, the insider directly owned 307,457 shares of the company’s stock, valued at $2,167,571.85. The trade was a 3.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 98,090 shares of company stock valued at $787,920. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently made changes to their positions in the business. Deltec Asset Management LLC grew its stake in Ocular Therapeutix by 6.0% in the third quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company’s stock valued at $20,123,000 after purchasing an additional 147,400 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Ocular Therapeutix during the 2nd quarter worth about $5,099,000. Dimensional Fund Advisors LP acquired a new position in shares of Ocular Therapeutix in the first quarter valued at approximately $5,491,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Ocular Therapeutix by 145.9% during the first quarter. The Manufacturers Life Insurance Company now owns 227,808 shares of the biopharmaceutical company’s stock worth $1,930,000 after buying an additional 135,160 shares in the last quarter. Finally, Second Line Capital LLC boosted its holdings in Ocular Therapeutix by 20.9% in the 2nd quarter. Second Line Capital LLC now owns 638,640 shares of the biopharmaceutical company’s stock valued at $6,271,000 after purchasing an additional 110,350 shares during the period. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

Featured Stories

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.